RU2529373C2 - Фармацевтическое средство, содержащее эпитопные пептиды hig2 и urlc10, для лечения рака, способы и средства для индукции антигенпрезентирующей клетки и цитотоксического т-лимфоцита (цтл), антигенпрезентирующая клетка и цтл, полученные таким способом, способ и средство индукции иммунного противоопухолевого ответа - Google Patents

Фармацевтическое средство, содержащее эпитопные пептиды hig2 и urlc10, для лечения рака, способы и средства для индукции антигенпрезентирующей клетки и цитотоксического т-лимфоцита (цтл), антигенпрезентирующая клетка и цтл, полученные таким способом, способ и средство индукции иммунного противоопухолевого ответа Download PDF

Info

Publication number
RU2529373C2
RU2529373C2 RU2011110376/10A RU2011110376A RU2529373C2 RU 2529373 C2 RU2529373 C2 RU 2529373C2 RU 2011110376/10 A RU2011110376/10 A RU 2011110376/10A RU 2011110376 A RU2011110376 A RU 2011110376A RU 2529373 C2 RU2529373 C2 RU 2529373C2
Authority
RU
Russia
Prior art keywords
antigen
peptide
hla
cancer
peptides
Prior art date
Application number
RU2011110376/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2011110376A (ru
Inventor
Такуя Цунода
Рюдзи ОХСАВА
Сатико Йосимура
Original Assignee
Онкотерапи Сайенс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкотерапи Сайенс, Инк. filed Critical Онкотерапи Сайенс, Инк.
Publication of RU2011110376A publication Critical patent/RU2011110376A/ru
Application granted granted Critical
Publication of RU2529373C2 publication Critical patent/RU2529373C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2011110376/10A 2008-08-19 2009-08-14 Фармацевтическое средство, содержащее эпитопные пептиды hig2 и urlc10, для лечения рака, способы и средства для индукции антигенпрезентирующей клетки и цитотоксического т-лимфоцита (цтл), антигенпрезентирующая клетка и цтл, полученные таким способом, способ и средство индукции иммунного противоопухолевого ответа RU2529373C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8997208P 2008-08-19 2008-08-19
US61/089,972 2008-08-19
PCT/JP2009/003897 WO2010021112A1 (en) 2008-08-19 2009-08-14 Hig2 and urlc10 epitope peptide and vaccines containing the same

Publications (2)

Publication Number Publication Date
RU2011110376A RU2011110376A (ru) 2012-09-27
RU2529373C2 true RU2529373C2 (ru) 2014-09-27

Family

ID=41707003

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011110376/10A RU2529373C2 (ru) 2008-08-19 2009-08-14 Фармацевтическое средство, содержащее эпитопные пептиды hig2 и urlc10, для лечения рака, способы и средства для индукции антигенпрезентирующей клетки и цитотоксического т-лимфоцита (цтл), антигенпрезентирующая клетка и цтл, полученные таким способом, способ и средство индукции иммунного противоопухолевого ответа

Country Status (16)

Country Link
US (1) US9119800B2 (OSRAM)
EP (1) EP2328600B9 (OSRAM)
JP (1) JP5633025B2 (OSRAM)
KR (1) KR101713581B1 (OSRAM)
CN (2) CN104958753B (OSRAM)
AU (1) AU2009283763B2 (OSRAM)
BR (1) BRPI0917391A2 (OSRAM)
CA (1) CA2734467C (OSRAM)
DK (1) DK2328600T3 (OSRAM)
ES (1) ES2566011T3 (OSRAM)
IL (1) IL211117A (OSRAM)
MX (2) MX337756B (OSRAM)
RU (1) RU2529373C2 (OSRAM)
SG (2) SG10201610206VA (OSRAM)
TW (2) TWI543767B (OSRAM)
WO (1) WO2010021112A1 (OSRAM)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2780020C2 (ru) * 2017-04-26 2022-09-19 Еурека Терапьютикс, Инк. Клетки, экспрессирующие химерные активирующие рецепторы и химерные стимулирующие рецепторы, и их применение
US11510971B2 (en) 2015-08-10 2022-11-29 Toray Industries, Inc. Immune inducer
US11613573B2 (en) 2017-04-26 2023-03-28 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
US11673915B2 (en) 2015-08-12 2023-06-13 Oncotherapy Science, Inc. DEPDC1-derived peptide and vaccine containing same

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI610939B (zh) * 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
SI2640842T1 (sl) * 2010-11-17 2018-09-28 Aduro Biotech, Inc. Postopki in sestavki za induciranje imunskega odziva na EGFRvIII
JP6255594B2 (ja) 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＬＹ６Ｋエピトープペプチドおよびこれを含有するワクチン
US10576097B2 (en) * 2014-08-04 2020-03-03 Oncotherapy Science, Inc. URLC10-derived peptide and vaccine containing same
PL3538645T3 (pl) 2017-06-20 2021-11-08 Institut Curie Komórki odpornościowe z defektem suv39h1
CN115300609A (zh) * 2021-05-08 2022-11-08 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019475A2 (en) * 2003-08-20 2005-03-03 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
WO2006090810A2 (en) * 2005-02-25 2006-08-31 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
WO2007029778A1 (ja) * 2005-09-07 2007-03-15 Nec Corporation Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
RU2451521C2 (ru) * 2006-06-16 2012-05-27 Онкотерапи Сайенс, Инк. Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070014787A1 (en) 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
AU6318300A (en) * 1999-08-05 2001-03-05 Kyogo Itoh Tumor antigen
WO2001023426A2 (en) 1999-09-30 2001-04-05 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
JP2005506033A (ja) 2000-10-13 2005-03-03 イーオーエス バイオテクノロジー インコーポレイテッド 前立腺癌の診断法、前立腺癌モジュレータースクリーニングの組成物及び方法
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20070015271A1 (en) 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2570392A1 (en) * 2004-06-21 2005-12-29 Green Peptide Co., Ltd. Peptide vaccine for cancer therapy
CN101175862A (zh) 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
CA2599875A1 (en) 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
JP2009502112A (ja) 2005-07-28 2009-01-29 オンコセラピー・サイエンス株式会社 腎細胞癌を診断および処置するための方法
JP4840858B2 (ja) * 2006-03-16 2011-12-21 学校法人慶應義塾 癌ワクチン
TWI610939B (zh) 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
US20100291091A1 (en) 2007-07-30 2010-11-18 ONCOTHERAPY SCIENCE ,inc. Cancer associated gene ly6k
TW201000115A (en) 2008-06-11 2010-01-01 Oncotherapy Science Inc IQGAP3 epitope peptides and vaccines containing the same
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019475A2 (en) * 2003-08-20 2005-03-03 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
WO2006090810A2 (en) * 2005-02-25 2006-08-31 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
WO2007029778A1 (ja) * 2005-09-07 2007-03-15 Nec Corporation Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
RU2451521C2 (ru) * 2006-06-16 2012-05-27 Онкотерапи Сайенс, Инк. Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11510971B2 (en) 2015-08-10 2022-11-29 Toray Industries, Inc. Immune inducer
US11673915B2 (en) 2015-08-12 2023-06-13 Oncotherapy Science, Inc. DEPDC1-derived peptide and vaccine containing same
RU2780020C2 (ru) * 2017-04-26 2022-09-19 Еурека Терапьютикс, Инк. Клетки, экспрессирующие химерные активирующие рецепторы и химерные стимулирующие рецепторы, и их применение
US11613573B2 (en) 2017-04-26 2023-03-28 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
US11965021B2 (en) 2017-04-26 2024-04-23 Eureka Therapeutics, Inc. Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
RU2784531C2 (ru) * 2017-06-20 2022-11-28 Энститю Кюри ИММУННЫЕ КЛЕТКИ, ДЕФЕКТНЫЕ ПО Suv39h1

Also Published As

Publication number Publication date
CN104958753B (zh) 2018-09-25
SG193806A1 (en) 2013-10-30
AU2009283763A2 (en) 2011-07-07
KR101713581B1 (ko) 2017-03-08
JP2012500184A (ja) 2012-01-05
TWI543767B (zh) 2016-08-01
MX355054B (es) 2018-04-03
EP2328600A1 (en) 2011-06-08
CA2734467A1 (en) 2010-02-25
US20110243973A1 (en) 2011-10-06
CN104958753A (zh) 2015-10-07
TW201019952A (en) 2010-06-01
US9119800B2 (en) 2015-09-01
EP2328600B1 (en) 2016-01-27
KR20110045052A (ko) 2011-05-03
CN102186491B (zh) 2015-06-10
MX2011001883A (es) 2011-03-29
WO2010021112A1 (en) 2010-02-25
CA2734467C (en) 2017-10-03
IL211117A0 (en) 2011-04-28
SG10201610206VA (en) 2017-01-27
AU2009283763A1 (en) 2010-02-25
IL211117A (en) 2017-03-30
HK1157204A1 (zh) 2012-06-29
BRPI0917391A2 (pt) 2015-12-01
JP5633025B2 (ja) 2014-12-03
CN102186491A (zh) 2011-09-14
DK2328600T3 (en) 2016-03-29
EP2328600B9 (en) 2016-07-13
RU2011110376A (ru) 2012-09-27
TWI580431B (zh) 2017-05-01
ES2566011T3 (es) 2016-04-08
TW201500055A (zh) 2015-01-01
AU2009283763B2 (en) 2014-06-19
EP2328600A4 (en) 2013-03-06
MX337756B (es) 2016-03-17

Similar Documents

Publication Publication Date Title
US20110280898A1 (en) Inhbb epitope peptides and vaccines containing the same
EP2303912B1 (en) Cdca1 epitope peptides and vaccines containing the same
RU2529373C2 (ru) Фармацевтическое средство, содержащее эпитопные пептиды hig2 и urlc10, для лечения рака, способы и средства для индукции антигенпрезентирующей клетки и цитотоксического т-лимфоцита (цтл), антигенпрезентирующая клетка и цтл, полученные таким способом, способ и средство индукции иммунного противоопухолевого ответа
US9675680B2 (en) MELK epitope peptides and vaccines containing the same
RU2496787C2 (ru) Пептиды эпитопов mybl2 и содержащие их вакцины
CN102119169A (zh) Iqgap3表位肽及包含它的疫苗
HK1157204B (en) Hig2 and urlc10 epitope peptide and vaccines containing the same
HK1155757A (en) Cdca1 epitope peptides and vaccines containing the same

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180815